Asset Details
Do you wish to reserve the book?
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Do you wish to request the book?
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
2015
Overview
The combination of a CTLA-4 blocker and a PD-1 blocker produced responses in more than 60% of previously untreated patients with
BRAF
wild-type advanced melanoma, including complete responses in more than 20% of these patients.
Recent approaches to the treatment of metastatic melanoma enhance antitumor immunity by blocking immune checkpoints, such as cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and the programmed death 1 (PD-1) receptor. Ipilimumab, an anti–CTLA-4 antibody, is approved by the Food and Drug Administration (FDA) on the basis of improvement in overall survival among patients with advanced melanoma, with objective responses in approximately 11% of the patients.
1
,
2
Nivolumab, an anti–PD-1 monoclonal antibody, has recently been shown to improve overall survival, as compared with dacarbazine (objective response rate, 40% vs. 14%), among previously untreated patients with advanced
BRAF
wild-type melanoma.
3
Nivolumab is approved . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Female
/ Humans
/ Male
/ Melanoma
/ Patients
/ Proto-Oncogene Proteins B-raf - genetics
/ Tumors
